Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA-Reference-Cited by-同舟云学术

Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA

Published:2021-08 Issue:2 Volume:80 Page:243-253
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Sumanasuriya Semini,Seed George,Parr Harry,Christova Rossitza,Pope Lorna,Bertan Claudia,Bianchini Diletta,Rescigno Pasquale,Figueiredo Ines,Goodall Jane,Fowler Gemma,Flohr Penelope,Mehra Niven,Neeb Antje,Rekowski Jan,Eisenberger Mario,Sartor Oliver,Oudard Stéphane,Geffriaud-Ricouard Christine,Ozatilgan Ayse,Chadjaa Mustapha,Macé Sandrine,Lord Chris,Baxter Joe,Pettitt Stephen,Lambros Maryou,Sharp Adam,Mateo Joaquin,Carreira Suzanne,Yuan Wei,de Bono Johann S.^ORCID

Funder

Sanofi-Aventis US LLC

Prostate Cancer UK

Cancer Research UK Lincoln's Inn Fields Laboratories

Publisher

Elsevier BV

Subject

Urology

Reference34 articles.

1. Cancer statistics, 2019;Siegel;CA Cancer J Clin,2019

2. Metastatic prostate cancer;Sartor;N Engl J Med,2018

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004